Insiders · SABS

SABS insider transactions

SAB Biotherapeutics Inc. (SABS) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for SABS

• 74d
  SEC Form 4 filed by Kropotova Alexandra

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 122d
  SEC Form 4 filed by PRESIDENT Sullivan Eddie Joe

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 122d
  SEC Form 4 filed by CEO Reich Samuel J

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 122d
  SEC Form 4 filed by CHIEF OPERATING OFFICER Bausch Christoph Lawrence

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 122d
  SEC Form 4 filed by CHIEF MEDICAL OFFICER Kropotova Alexandra

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 122d
  SEC Form 4 filed by Officer To Lucy

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 151d
  SEC Form 4 filed by Director Jain Rita

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 151d
  SEC Form 4 filed by Director Zaccardelli David

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 151d
  SEC Form 3 filed by new insider Jain Rita

  3 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 151d
  SEC Form 3 filed by new insider Zaccardelli David

  3 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 171d
  SEC Form 4 filed by Director Skyler Jay S

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 171d
  SEC Form 4 filed by Director Polvino William James

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 171d
  SEC Form 4 filed by Director Lucera Erick

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 171d
  SEC Form 4 filed by Director Ellias Helen K.

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 171d
  SEC Form 4 filed by Director Giberson Scott

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 171d
  SEC Form 4 filed by Director Link David

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 177d
  CHIEF MEDICAL OFFICER Kropotova Alexandra covered exercise/tax liability with 988 shares, decreasing direct ownership by 2% to 44,284 units (SEC Form 4)

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 249d
  Director Moin Andrew exercised 1,740,000 shares at a strike of $1.75 (SEC Form 4)

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 249d
  Director Sessa Capital (Master), L.P. exercised 1,740,000 shares at a strike of $1.75 (SEC Form 4)

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 258d
  CHIEF MEDICAL OFFICER Kropotova Alexandra covered exercise/tax liability with 1,977 shares, decreasing direct ownership by 4% to 45,272 units (SEC Form 4)

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 283d
  SEC Form 4 filed by CEO & EXECUTIVE CHAIRMAN Reich Samuel J

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 283d
  SEC Form 4 filed by Officer To Lucy

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 283d
  SEC Form 4 filed by CHIEF MEDICAL OFFICER Kropotova Alexandra

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 283d
  SEC Form 4 filed by CHIEF OPERATING OFFICER Bausch Christoph Lawrence

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 283d
  SEC Form 4 filed by PRESIDENT Sullivan Eddie Joe

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 318d
  SEC Form 4 filed by Director Sessa Capital (Master), L.P.

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 318d
  SEC Form 4 filed by Director Moin Andrew

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 432d
  CHIEF MEDICAL OFFICER Kropotova Alexandra covered exercise/tax liability with 1,179 shares, decreasing direct ownership by 2% to 47,249 units (SEC Form 4)

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 523d
  CHIEF MEDICAL OFFICER Kropotova Alexandra covered exercise/tax liability with 9,072 shares, decreasing direct ownership by 16% to 48,428 units (SEC Form 4)

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 579d
  SEC Form 4 filed by Director Ellias Helen K.

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 663d
  SEC Form 4 filed by Officer To Lucy

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 676d
  SEC Form 3 filed by new insider To Lucy

  3 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 690d
  SEC Form 4 filed by Director Spragens Jeffrey G

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 690d
  SEC Form 4 filed by Director Polvino William James

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 690d
  SEC Form 4 filed by CEO & EXECUTIVE CHAIRMAN Reich Samuel J

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 690d
  SEC Form 4 filed by Director Skyler Jay S

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 690d
  SEC Form 4 filed by Director Link David Charles

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 690d
  SEC Form 4 filed by Director Giberson Scott

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 690d
  SEC Form 4 filed by PRESIDENT Sullivan Eddie Joe

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 690d
  SEC Form 4 filed by Director Lucera Erick

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 690d
  SEC Form 4 filed by Director Hamilton Christine E

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 713d
  SEC Form 3 filed by new insider Conley Mark William

  3 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 754d
  SEC Form 3 filed by new insider Skyler Jay S

  3 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 835d
  SEC Form 4 filed by Kropotova Alexandra

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 835d
  SEC Form 4 filed by Bausch Christoph Lawrence

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 835d
  SEC Form 4 filed by Sullivan Eddie Joe

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 835d
  SEC Form 4 filed by King Michael

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 835d
  SEC Form 4 filed by Reich Samuel J

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 912d
  Sullivan Eddie Joe bought $1,531 worth of shares (1,740 units at $0.88), increasing direct ownership by 0.03% to 5,232,304 units (SEC Form 4)

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 920d
  King Michael bought $4,500 worth of shares (5,000 units at $0.90) (SEC Form 4)

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 920d
  Reich Samuel J bought $9,842 worth of shares (11,000 units at $0.89), increasing direct ownership by 5% to 219,001 units (SEC Form 4)

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 922d
  Sessa Capital (Master), L.P. converted options into 4,584,571 shares (SEC Form 4)

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 922d
  Moin Andrew converted options into 4,584,571 shares (SEC Form 4)

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 922d
  Ellias Helen K. converted options into 2,857,142 shares (SEC Form 4)

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 928d
  SEC Form 3 filed by new insider Ellias Helen K.

  3 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 935d
  SEC Form 4 filed by Moin Andrew (Amendment)

  4/A - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 935d
  SEC Form 4 filed by Sessa Capital (Master), L.P. (Amendment)

  4/A - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 936d
  SEC Form 4 filed by Moin Andrew

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 947d
  SEC Form 4 filed by King Michael

  4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
• 947d
  SEC Form 3 filed by new insider King Michael

  3 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)